London – Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK) (NASDAQ Dubai: HIK), the leading multinational pharmaceutical company in the Middle East and North Africa region, the USA and Europe, is pleased to announce that it was the recipient of the ‘Best Company in an Emerging Market Award’ at the 5th Annual Scrip Awards held in London on 18 November 2009.
Scrip World Pharmaceutical News- the flagship title of the global pharmaceutical industry – recognises, through these Awards, the essential but often undervalued contribution of pharmaceutical and biotech companies to the improvement of healthcare worldwide.
Hikma won the award in recognition of its excellent performance across a range of business activities and in strong competition against a number of leading emerging market pharmaceutical companies.
Hikma’s Chairman, Mr Samih Darwazah, who founded the Company in 1978 in Amman, Jordan, accepted the award on behalf of the Company.
Hikma is market leader in developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Its production facilities are located across its different markets such as Jordan*, Saudi Arabia**,